Latest news

Teckningsperioden i Nanologicas företrädesemission inleds 11 mars och pågår till och med 25 mars. Teckning med stöd av företrädesrätt Teckning av aktier med stöd av teckningsrätter sker genom samtidig kontant betalning under perioden från och med den 11 mars 2026 till och med den 25 mars 2026. Observera att det kan ta upp till tre bankdagar för betalningen att nå mottagarkontot. Teckning och betalning ska ske i enlighet med något av nedanstående två alternativ. Emissionsredovisning

The nomination committee of Nanologica proposes to the Annual General Meeting on May 21 that Mark Quick and Erik Haeffler be elected as new members of the board of directors of Nanologica AB. Furthermore, Thomas Eldered is proposed as new chairman of the board. Mark Quick works as a Partner at Flerie AB having previously worked at Recipharm where he was Head of Corporate Development leading the M&A activities. Prior to that he held positions

Nanologica AB (publ) (”Nanologica” or ”the Company”) hereby announces the outcome of the two directed issues of shares resolved by the board of directors on 30 January 2026 and approved by the extraordinary general meeting on 4 March 2026. The directed issues comprised a total of 34,203,780 shares. All shares have been subscribed for and allotted in accordance with the resolutions. Ardena Sweden AB has subscribed for and been allotted all 21,453,780 shares in the

Nanologica AB (publ) (”Nanologica” or ”the Company”) publishes an information document regarding the directed share issues of approximately SEK 13.7 million in total and rights issue of approximately SEK 82.5 million, before issue costs, which was resolved by the board of directors on 30 January 2026 and subsequently approved by the extraordinary general meeting held on 4 March 2026 (“The Issues”). The information document has been registered with the Swedish Financial Supervisory Authority and is

Nanologica AB (publ) (“Nanologica” or the “Company”) held an extraordinary general meeting today at which the following resolutions were passed. For more detailed information on the content of the resolutions, please refer to the complete notice of the extraordinary general meeting, which is available on the Company’s website, www.nanologica.com. Adoption of new articles of association The general meeting resolved to amend the articles of association, whereby the limits of the articles of association for share

FINANCIAL SUMMARY Net sales for the fourth quarter amounted to SEK 5,205 thousand (6,715) and for the full year to SEK 21,127 thousand (14,538) Operating loss for the quarter amounted to SEK -15,706 thousand (-11,890) and for the full year to SEK -46,801 thousand (-59,255) Loss after tax for the quarter amounted to SEK -16,733 thousand (-14,033) and for the full year to SEK -51,289 thousand (-65,629) Earnings per share before and after dilution were